Literature DB >> 2280241

Modern haemophilia treatment: medical improvements and quality of life.

F R Rosendaal1, C Smit, I Varekamp, A H Bröcker-Vriends, H van Dijck, T P Suurmeijer, J P Vandenbroucke, E Briët.   

Abstract

Adequate replacement therapy in haemophilia has been available for two decades. This has led to considerable improvements in the life expectancy and physical status of haemophilia patients. A study was conducted to investigate whether this has also led to improvements in quality of life. With this aim, information was obtained from 935 Dutch haemophiliacs by mailed questionnaires on relationships, marriage, family life and employment. Haemophilia patients were less often married than men in the general population (13% fewer) and had a lower total number of children (30% lower, 17% for those who were married). Twenty-two per cent of the patients were not employed and received an income from the disability funds. While severity of haemophilia, joint damage and age increased the risk of disability, it was noted that home treatment was associated with a 50% reduction in this risk. Remarkably, haemophilia patients did not differ from the general population in their view of the quality of their own health. The results of this study show a positive influence of modern haemophilia treatment on quality of life. At present, AIDS overshadows all optimistic feelings one may have about this field. However, the results described here demonstrate the benefits that can be achieved with adequate replacement therapy, and justify the expectation of further improvements in the near future.

Entities:  

Mesh:

Year:  1990        PMID: 2280241     DOI: 10.1111/j.1365-2796.1990.tb00291.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

1.  Sex ratio of the mutation frequencies in haemophilia A: coagulation assays and RFLP analysis.

Authors:  A H Bröcker-Vriends; F R Rosendaal; J C van Houwelingen; E Bakker; G J van Ommen; J J van de Kamp; E Briët
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

Review 2.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

3.  Septic arthritis in males with haemophilia.

Authors:  A A Ashrani; N S Key; J Michael Soucie; N Duffy; A Forsyth; S Geraghty
Journal:  Haemophilia       Date:  2008-02-21       Impact factor: 4.287

4.  Assessing quality of life in individuals with hereditary blood coagulation disorders.

Authors:  S Solovieva; N Santavirta; S Santavirta; Y T Konttinen
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

Review 5.  The contribution of DNA analysis to carrier detection and prenatal diagnosis of hemophilia A and B.

Authors:  A H Bröcker-Vriends; E Bakker; H H Kanhai; G J van Ommen; P H Reitsma; J J van de Kamp; E Briët
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 6.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.

Authors:  H J Longhurst; S Carr; K Khair
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

8.  Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries.

Authors:  Ernesto Cimino; Silvia Linari; Mara Malerba; Susan Halimeh; Francesca Biondo; Martina Westfeld
Journal:  Patient Prefer Adherence       Date:  2014-12-12       Impact factor: 2.711

Review 9.  Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.

Authors:  Amy D Shapiro
Journal:  Vasc Health Risk Manag       Date:  2007

Review 10.  Physical and psychosocial challenges in adult hemophilia patients with inhibitors.

Authors:  Sue duTreil
Journal:  J Blood Med       Date:  2014-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.